ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 107 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $44 | -48.2% | 40,245 | -41.0% | 0.00% | – |
Q1 2024 | $85 | -53.8% | 68,266 | -61.2% | 0.00% | – |
Q4 2023 | $184 | -88.5% | 175,919 | -24.9% | 0.00% | -100.0% |
Q3 2023 | $1,603 | +81.1% | 234,150 | +174.2% | 0.00% | 0.0% |
Q2 2023 | $885 | -42.0% | 85,389 | -54.7% | 0.00% | – |
Q1 2023 | $1,526 | +126.4% | 188,690 | +340.8% | 0.00% | – |
Q4 2022 | $674 | -99.7% | 42,810 | +156.2% | 0.00% | – |
Q3 2022 | $263,000 | -14.3% | 16,707 | -24.0% | 0.00% | – |
Q2 2022 | $307,000 | -70.5% | 21,969 | -63.5% | 0.00% | -100.0% |
Q1 2022 | $1,039,000 | -64.4% | 60,256 | -70.0% | 0.00% | 0.0% |
Q4 2021 | $2,922,000 | +223.6% | 201,036 | +300.7% | 0.00% | – |
Q3 2021 | $903,000 | +340.5% | 50,169 | +326.4% | 0.00% | – |
Q2 2021 | $205,000 | – | 11,767 | +65272.2% | 0.00% | – |
Q1 2021 | $0 | – | 18 | 0.0% | 0.00% | – |
Q4 2020 | $0 | – | 18 | 0.0% | 0.00% | – |
Q3 2020 | $0 | -100.0% | 18 | -99.8% | 0.00% | – |
Q2 2020 | $13,000 | +18.2% | 8,294 | -21.1% | 0.00% | – |
Q1 2020 | $11,000 | -93.1% | 10,516 | -87.5% | 0.00% | – |
Q4 2019 | $159,000 | +783.3% | 83,853 | +389.9% | 0.00% | – |
Q3 2019 | $18,000 | -64.0% | 17,118 | -25.6% | 0.00% | – |
Q2 2019 | $50,000 | -20.6% | 23,015 | +119.5% | 0.00% | – |
Q1 2019 | $63,000 | -64.6% | 10,483 | -14.4% | 0.00% | – |
Q3 2018 | $178,000 | +356.4% | 12,243 | +523.4% | 0.00% | – |
Q2 2018 | $39,000 | -64.9% | 1,964 | -69.2% | 0.00% | – |
Q1 2018 | $111,000 | -0.9% | 6,378 | +40.7% | 0.00% | – |
Q4 2017 | $112,000 | -41.7% | 4,532 | -39.2% | 0.00% | – |
Q3 2017 | $192,000 | +1180.0% | 7,457 | +1248.5% | 0.00% | – |
Q2 2017 | $15,000 | -91.0% | 553 | -90.1% | 0.00% | – |
Q1 2017 | $167,000 | +15.2% | 5,608 | +4.8% | 0.00% | – |
Q4 2016 | $145,000 | +3525.0% | 5,350 | +3396.7% | 0.00% | – |
Q3 2016 | $4,000 | -84.6% | 153 | -84.7% | 0.00% | – |
Q4 2015 | $26,000 | – | 1,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |